Hazel Morrison
Overview
Explore the profile of Hazel Morrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
2793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fredsgaard-Jones T, Harris S, Morrison H, Ateere A, Nassanga B, Ramon R, et al.
Front Immunol
. 2024 Nov;
15:1427371.
PMID: 39611145
Introduction: Tuberculosis (TB) is the leading cause of death worldwide from a single infectious agent. Bacillus Calmette-Guérin (BCG), the only licensed vaccine, provides limited protection. Controlled human infection models (CHIMs)...
2.
Ongarj J, Intapiboon P, Surasombatpattana S, Satti I, Harris S, Morrison H, et al.
Tuberculosis (Edinb)
. 2024 Jun;
148:102533.
PMID: 38878478
Tuberculosis (TB) is an infectious disease with the burden concentrated in low- and middle-income countries. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with widespread inflammation that is prevalent...
3.
Jackson S, Marshall J, Mawer A, Lopez-Ramon R, Harris S, Satti I, et al.
Lancet Microbe
. 2024 May;
5(7):655-668.
PMID: 38703782
Background: A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×10 50% tissue culture infectious dose (TCID) pre-alpha SARS-CoV-2 virus. Given...
4.
Satti I, Marshall J, Harris S, Wittenberg R, Tanner R, Ramon R, et al.
Lancet Infect Dis
. 2024 Apr;
24(8):909-921.
PMID: 38621405
Background: Mycobacterium tuberculosis is the main causative agent of tuberculosis. BCG, the only licensed vaccine, provides inadequate protection against pulmonary tuberculosis. Controlled human infection models are useful tools for vaccine...
5.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, et al.
Lancet Infect Dis
. 2024 Jan;
24(2):e78-e79.
PMID: 38184003
No abstract available.
6.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, et al.
Lancet Infect Dis
. 2023 Nov;
24(3):285-296.
PMID: 38012890
Background: BCG confers reduced, variable protection against pulmonary tuberculosis. A more effective vaccine is needed. We evaluated the safety and immunogenicity of candidate regimen ChAdOx1 85A-MVA85A compared with BCG revaccination...
7.
Morrison H, Jackson S, McShane H
Front Immunol
. 2023 Jun;
14:1211388.
PMID: 37304270
Controlled Human Infection Models (CHIMs) involve deliberately exposing healthy human volunteers to a known pathogen, to allow the detailed study of disease processes and evaluate methods of treatment and prevention,...
8.
Morrison H, Perrin F, Dedicoat M, Ahmed R, Brown J, Loughenbury M, et al.
J Infect
. 2023 Apr;
87(1):59-61.
PMID: 37044162
No abstract available.
9.
Hodgson S, Iveson P, Larwood J, Roche S, Morrison H, Cosgrove C, et al.
Clin Transl Sci
. 2021 Oct;
15(2):524-534.
PMID: 34670021
The safety of novel therapeutics and vaccines are typically assessed in early phase clinical trials involving "healthy volunteers." Abnormalities in such individuals can be difficult to interpret and may indicate...
10.
Dipper A, Morrison H, Jones R
Br J Hosp Med (Lond)
. 2021 Jun;
82(5):1-2.
PMID: 34076515
No abstract available.